Azilsartan Medoxomil

  • # LGM Pharma is a Azilsartan Medoxomil CAS# 863031-21-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Azilsartan Medoxomil
  • CAS #: 863031-21-4
  • Mode of Action:

    Azilsartan medoxomil blocks the angiotensin II type 1 receptor preventing angiotensin II from binding and causing vasoconstriction. Azilsartan's ability to remain tightly bound to AT1 receptors for very long periods after drug washout is among its most unusual features.

  • Pharmacodynamics:

    Azilsartan medoxomil decreases the pressor effect of angiotensin II. In response, angiotensin I, angiotensin II, and renin are increased while aldosterone is decreased.

  • Metabolism:

    Azilsartan is metabolized by CYP2C9. CYP2C9 carries out decarboxylation of azilsartan to M-I, and O-dealkylation of azilsartan to M-II. Both M-I and M-II have no pharmacologic activity.

  • Toxicity:

    Hypotension and diarrhea are most common.

  • IUPAC: 1H-Benzimidazole-7-carboxylic acid, 1-((2'-(2, 5-dihydro-5- oxo-1, 2, 4-oxadiazol-3-yl)(1, 1'-biphenyl)-4-yl)methyl)-2- ethoxy-, (5-methyl-2-oxo-1, 3-dioxol-4-yl)methyl ester
  • ATC: C09CA09
  • DrugBank: DB08822
  • Formula: C30-H24-N4-O8
  • Molecular Mass: 568.5336
  • Synonyms: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4- oxadiazol-3-yl)biphenyl-2-yl)methyl)-1H-benzo(d)imidazole-7-carboxylate, Azilsartan medoxomil, Edarbi, TAK 491, TAK-491, UNII-LL0G25K7I2
  • SMILES: c1(ccc(cc1)c1ccccc1c1noc(=O)[nH]1)Cn1c(nc2c1c(ccc2)C(=O)OCc1oc(=O)oc1C)OCC
  • AHFS Code: 24:32.1
  • InChl: InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
  • General Reference:


    1. Jones JD, Jackson SH, Agboton C, Martin TS: Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker. P T. 2011 Oct;36(10):634-40. Pubmed
    2. Lanier G, Sankholkar K, Aronow WS: Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin-Angiotensin-Aldosterone System Antagonists. Am J Ther. 2012 Sep 12. Pubmed
    3. Kurtz TW, Kajiya T: Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133-43. doi: 10.2147/VHRM.S22595. Epub 2012 Feb 28. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service